Latest Uk Market News

GWA Group Limited reported a 1.9% revenue increase and a 3.2% rise in normalized EBIT for the half year ended December 2024, alongside a 7.1% lift in its interim dividend, reflecting disciplined execution despite tough market conditions.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Wellnex Life Limited has initiated a $22.1 million entitlement offer priced at $0.65 per share, coinciding with its proposed dual listing on the London Stock Exchange's AIM market, driven by strong UK institutional interest.

Nick Scali Limited reported a robust 1H FY25 with revenue growth and profits exceeding guidance, despite ongoing UK market disruptions and restructuring costs.

PEXA Group Limited announced the resignation of its Australian CEO, Les Vance, effective February 21, 2025, marking a significant leadership change for the digital property exchange giant.

Simble Solutions reports a robust Q4 FY24 with a 117% jump in customer receipts and a strategic $280k capital placement, underpinning its growth in energy and sustainability software.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.